

9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982

Email: info@abeomics.com

12-4255: Phospho-c-Cbl (Tyr700) (Clone: E1) rabbit mAb

Clonality: Monoclonal **Clone Name:** CblY700-E1 Application: FACS

Reactivity: Human, Mouse, Rat Unconjugated Conjugate: Format: **Purified**

E3 ubiquitin-protein ligase CBL, Casitas B-lineage lymphoma proto-oncogene, Proto-oncogene

Alternative Name: c-Cbl, RING finger protein 55, RING-type E3 ubiquitin transferase, Signal transduction protein

CBL, CBL2, RNF55

Rabbit IgG1k Isotype:

A synthetic phospho-peptide corresponding to residues surrounding Tyr700 of human **Immunogen Information:**

phospho c-Cbl

Description

The c-Cbl (Casitas B-lineage Lymphoma) proto-oncogene is a ubiquitously expressed cytoplasmic adaptor protein that contains multiple functional domains, including an amino-terminal tyrosine kinase-binding (TKB) domain, a RING finger motif, and a proline-rich region. The TKB recognizes phosphorylated tyrosines on activated receptor tyrosine kinases (RTKs) and on other nonreceptor tyrosine kinases, while the RING finger motif recruits ubiquitin-conjugating enzymes. These two domains are primarily responsible for the ubiquitin ligase activity of c-Cbl and downregulation of RTKs (1). The proline-rich region contains 14-3-3 protein-binding and SH3 domain-binding motifs. c-Cbl is phosphorylated at Y700, Y731, and Y774 by Sykand Src-family kinases after the stimulation of some integrins and a wide variety of receptors for immunoglobulins, antigens, hormones, growth factors, and cytokines. Phosphorylated Y774 interacts with the SH2 domain of Crk (1,2). The c-Cbl adapter protein is expressed in the cytoplasm in all tissues, with especially high levels of expression in hematopoietic cells (3,4). Through its many functional sites, c-Cbl plays key roles in the positive and negative regulation of vital cell functions, including T Cell Receptor-mediated cellular immune responses. In human cancer tissues, c-Cbl is frequently tyrosinephosphorylated in a tumor-specific manner (5).

Product Info

 $20 \mu l / 200 \mu l$ Amount:

Content: 1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA

Storage condition: Store at -20°C. Avoid repeated freeze and thaw cycles.

Application Note

 $1\tilde{A} \cap \hat{A} \cup \hat{A} \cup \hat{A} \cap \hat{A} \cup \hat{A} \cap \hat{A} \cup \hat{A} \cup$ See product image legends for additional information. (0.5mg/ml, more than 200 western blots)



9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982

Email: info@abeomics.com




Fig-1: Flow cytometric analysis of C6 cells secondary antibody only negative control (blue) or treated with imatinib (grey) or with pervanadate (orange) using $0.1~\mu g/mL$ isotype control or imatinib (red) or pervanadate (green) using Phospho-c-Cbl (Tyr700) antibody CblY700-E1 at $0.1~\mu g/mL$.




Fig 2 : Peptide blocking flow cytometric analysis of C6 cells, secondary antibody only negative control (light blue) or treated with imatinib (red) or with pervanadate (green) or imatinib and blocked with phospho-peptide (black) or pervanadate and blocked with phospho peptide (gold) or imatinib and blocked with non-phospho peptide (dark blue) or pervanadate and blocked with non-phospho peptide (purple) using Phospho-c-Cbl (Tyr700) antibody CblY700-E1 at 0.1 μg/mL.




Fig-3: Flow cytometric analysis of HeLa cells, secondary antibody only negative control (blue) or treated with imatinib (grey) or with pervanadate (orange) using 0.1 μ g/mL isotype control or imatinib (red) or pervanadate (green) using Phospho-c-Cbl (Tyr700) antibody CblY700-E1 at 0.1 μ g/mL.




Fig-4: Flow cytometric analysis of 3T3 cells, secondary antibody only negative control (blue) or treated with imatinib (red) or pervanadate (green) using Phospho-c-Cbl (Tyr700) antibody CblY700-E1 at 0.01 μ g/mL.